Stocks · News reference
Filed: 2026-09-10 AccNo: 0001628280-26-061218 Size: 176 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
David Smith, a current director on the Board, had acted as Interim Chief Financial Officer and principal financial officer during Mr. Knoblauch’s leave of absence. In connection with Mr. Knoblauch’s reinstatement, Mr.
Fortrea has signed a definitive agreement to acquire Worldwide Clinical Trials' Early Phase Services division for approximately $45 million. The acquisition includes a GLP bioanalytical lab in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biospecimen storage facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform and expands its early-phase capabilities, while allowing Worldwide to focus on its rapidly growing late-phase business in oncology, neuroscience, and rare diseases.
Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP-compliant bioanalytical laboratory in Austin, a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, and biospecimen storage facilities in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform from Phase 1 through Phase 4 trials and post-approval evidence generation, while allowing Worldwide to focus on its faster-growing late-stage clinical business in oncology, neuroscience, internal medicine, and rare diseases.